What if aesthetic contouring could be approached without surgery or heat-based fat reduction? In this episode of Proven Health Alternatives, I sit down with Joseph Zapolsky III and Travis Sammons from Erchonia Corporation to explore the development of non-thermal, low-level laser technology and its application in aesthetic medicine, particularly for targeting stubborn submental fat beneath the chin.
Together, we discuss Erchonia's FDA-cleared CLX laser, which uses green and violet wavelengths for non-invasive submental contouring. Our conversation examines the science behind these wavelengths, how photochemical approaches differ from traditional heat-based treatments, and why understanding the biological effects of light matters when evaluating aesthetic technologies. We also explore the clinical research, patient experience, and growing demand for non-surgical aesthetic options.
Whether you're a healthcare practitioner interested in emerging technologies or someone looking to understand the latest developments in non-invasive aesthetic treatments, this episode offers an inside look at how low-level laser therapy is expanding the possibilities in aesthetic medicine.
Key Takeaways:
-
Non-invasive Aesthetic Innovation: The CLX laser utilizes green and violet wavelengths to target under-chin fat effectively, without the need for invasive procedures or heat-based methods.
-
Scientific Advancements: Non-thermal laser technology opens temporary pores in fat cells to release triglycerides naturally, ensuring a safe and painless process.
-
Comprehensive Approach: The episode highlights the differences between laser and LED technologies, emphasizing the significance of wavelength and coherence in achieving optimal results.
-
Innovation in Laser Medicine: The combination of green and violet wavelengths in CLX laser treatments has proven to be efficient, with clinical studies showing high patient satisfaction rates.
-
Future Prospects: The exploration of non-thermal laser technology's potential continues, with future applications in skin laxity and neurological treatments on the horizon.
Travis Sammons is the Clinical Affairs Manager at Erchonia Corporation, a world leader in low-level laser technology. He oversees Erchonia's research department and is responsible for developing clinical protocols, guiding devices through the FDA regulatory pathway from Pre-Submission to 510(k) clearance, and publishing clinical data. His work focuses on advancing the science behind low-level laser therapy, including exploring new mechanisms of action and new clinical applications.
Joseph Zapolsky III is the International Sales Director at Erchonia Corporation, a pioneer in FDA-cleared low-level laser technologies. With nearly 25 years of experience at Erchonia, Joe has helped expand the company's international presence, develop strategic partnerships, and introduce innovative laser technologies to healthcare professionals worldwide. He works closely with practitioners and Erchonia's clinical and commercial teams to help bring new technologies to market and support their successful integration into clinical practice.
